TetraLogic Pharmaceuticals Corp
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to… Read more
TetraLogic Pharmaceuticals Corp - Asset Resilience Ratio
TetraLogic Pharmaceuticals Corp (TLOG) has an Asset Resilience Ratio of 7.98% as of December 2015. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2015)
This chart shows how TetraLogic Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down TetraLogic Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.11 Million | 7.98% |
| Total Liquid Assets | $5.11 Million | 7.98% |
Asset Resilience Insights
- Limited Liquidity: TetraLogic Pharmaceuticals Corp maintains only 7.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TetraLogic Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio
Compare TetraLogic Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for TetraLogic Pharmaceuticals Corp (2011–2015)
The table below shows the annual Asset Resilience Ratio data for TetraLogic Pharmaceuticals Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 7.98% | $5.11 Million | $64.02 Million | -26.37pp |
| 2014-12-31 | 34.34% | $40.62 Million | $118.29 Million | +34.31pp |
| 2013-12-31 | 0.04% | $20.00K | $55.50 Million | -0.37pp |
| 2012-12-31 | 0.41% | $20.00K | $4.89 Million | -33.39pp |
| 2011-12-31 | 33.80% | $5.53 Million | $16.35 Million | -- |